-+ 0.00%
-+ 0.00%
-+ 0.00%

Tempest Therapeutics Faces Nasdaq Delisting Over Stockholders' Equity Shortfall

PUBT·11/20/2026 21:07:13
Listen to the news
Tempest Therapeutics Faces Nasdaq Delisting Over Stockholders' Equity Shortfall
  • Tempest Therapeutics received a Nasdaq delisting notice on November 17, 2026, for failing to regain compliance with minimum stockholders' equity requirements.
  • Stockholders' equity was below $2.5 million at March 31, 2026, breaching Nasdaq Listing Rule 5550(b)(1).
  • A required capital-raising transaction was not completed by the extended November 16, 2026, compliance deadline.
  • The company plans to appeal; a timely hearing request would stay delisting, keeping its common stock trading on the Nasdaq Capital Market.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tempest Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-122694), on November 20, 2026, and is solely responsible for the information contained therein.